Report Pursuant to Section 28a of the Danish Securities Trading Act
4/25/2012 1:16 PM EST
Genmab A/S
Insiders' dealing
Report Pursuant to Section 28a of the Danish Securities Trading Act
Copenhagen, Denmark; April 25, 2012 – Pursuant to Section 28a of the Danish
Securities Trading Act, Genmab A/S (OMX: GEN) shall make public information on
transactions by managerial employees and their related parties involving Genmab
shares and related instruments, as follows:
Name: Daniel Bruno
Reason: Member of the Board of Directors
Issuer: Genmab A/S
ID code/ ISIN: DK0010272202
Description: Warrants
Transaction: Grant
Trading date: April 25, 2012
Market: NASDAQ OMX Copenhagen A/S
Number: 3,000
Value: DKK 66,960
The exercise price for each warrant is DKK 45.24. Each warrant entitles the
owner to subscribe one share of nominally DKK 1. On the basis of an exercise
price of DKK 45.24 and by application of the Black-Scholes formula, the average
value of each warrant can be calculated as DKK 22.32 based on an interest rate
of 0.8468% and the historical volatility of Genmab A/S shares calculated at
62.56%.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company’s first marketed
antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab’s validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab’s strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E:
This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax®-EGFr;
HuMax®-IL8; HuMax®-TAC; HuMax®-CD38; HuMax®-TF; HuMax®-Her2; HuMax®-cMet,
HuMax®-CD74, DuoBody™ and UniBody® are all trademarks of Genmab A/S. Arzerra®
is a trademark of GlaxoSmithKline.
Company Announcement no. 12
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark